Clearly NTcell does work better is some patients than others, which we already expected would be the case. In some, given enough time, its potentially an outstanding treatment (patient 1). In the remainder it does seem to halt progression. Lets be patient.
There is a lot here to be encouraged about here. If the 52 week data had not shown anything interesting I think they would have said so.
Ann: NTCELL and Parkinson's Clinical Trial Update, page-4
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $4.495K | 642.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4953269 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 954858 | 11 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |